{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:11:57Z","timestamp":1788459117624,"version":"build-2803163510"},"reference-count":57,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006920","name":"University of Pennsylvania","doi-asserted-by":"publisher","award":["SCR_010035"],"award-info":[{"award-number":["SCR_010035"]}],"id":[{"id":"10.13039\/100006920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002002","name":"Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000902","name":"Pediatric Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000902","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["F32 HL156600"],"award-info":[{"award-number":["F32 HL156600"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL142782"],"award-info":[{"award-number":["R01HL142782"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL166184"],"award-info":[{"award-number":["R01HL166184"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007234","name":"University of Chicago","doi-asserted-by":"publisher","award":["SCR_019196"],"award-info":[{"award-number":["SCR_019196"]}],"id":[{"id":"10.13039\/100007234","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007234","name":"University of Chicago","doi-asserted-by":"publisher","award":["SCR_017760"],"award-info":[{"award-number":["SCR_017760"]}],"id":[{"id":"10.13039\/100007234","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA231880"],"award-info":[{"award-number":["R01CA231880"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["T32CA009594"],"award-info":[{"award-number":["T32CA009594"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.bneo.2025.100119","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T18:20:37Z","timestamp":1747678837000},"page":"100119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["NAMPT haploinsufficiency is a collateral lethal therapeutic vulnerability in high-risk myeloid malignancies with TP53 inactivation"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8097-4010","authenticated-orcid":false,"given":"Madhavi D.","family":"Senagolage","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hunter Z.","family":"Blaylock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saira","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah J.","family":"Skuli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin P.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8260-3598","authenticated-orcid":false,"given":"Megan E.","family":"McNerney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.bneo.2025.100119_bib1","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1182\/blood-2006-04-014324","article-title":"Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B","volume":"108","author":"Fr\u00f6hling","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bneo.2025.100119_bib2","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1200\/JCO.2010.31.1175","article-title":"Unraveling the molecular pathophysiology of myelodysplastic syndromes","volume":"29","author":"Bejar","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.bneo.2025.100119_bib3","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1182\/blood.V93.2.459","article-title":"Myelodysplastic and myeloproliferative disorders of childhood: a study of 167 patients","volume":"93","author":"Luna-Fineman","year":"1999","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2025.100119_bib4","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2002-11-3343","article-title":"Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series","volume":"102","author":"Smith","year":"2003","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bneo.2025.100119_bib5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"issue":"24","key":"10.1016\/j.bneo.2025.100119_bib6","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1200\/JCO.2011.35.8135","article-title":"Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure","volume":"29","author":"Pr\u00e9bet","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.bneo.2025.100119_bib7","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/bjh.12964","article-title":"The spectrum of somatic mutations in high-risk acute myeloid leukaemia with -7\/del(7q)","volume":"166","author":"McNerney","year":"2014","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.bneo.2025.100119_bib8","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1038\/s41375-023-02003-x","article-title":"Genomics of deletion 7 and 7q in myeloid neoplasm: from pathogenic culprits to potential synthetic lethal therapeutic targets","volume":"37","author":"Mori","year":"2023","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.bneo.2025.100119_bib9","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/MOH.0000000000000699","article-title":"The significance of CUX1 and chromosome 7 in myeloid malignancies","volume":"29","author":"Jotte","year":"2022","journal-title":"Curr Opin Hematol"},{"issue":"2","key":"10.1016\/j.bneo.2025.100119_bib10","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41573-022-00571-8","article-title":"Drugging p53 in cancer: one protein, many targets","volume":"22","author":"Hassin","year":"2023","journal-title":"Nat Rev Drug Discov"},{"issue":"8872","key":"10.1016\/j.bneo.2025.100119_bib11","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/0140-6736(93)91764-D","article-title":"Gene deletion: a new target for cancer chemotherapy","volume":"342","author":"Frei","year":"1993","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.bneo.2025.100119_bib12","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.cell.2012.07.023","article-title":"Cancer vulnerabilities unveiled by genomic loss","volume":"150","author":"Nijhawan","year":"2012","journal-title":"Cell"},{"issue":"7559","key":"10.1016\/j.bneo.2025.100119_bib13","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nature14610","article-title":"Lenalidomide induces ubiquitination and degradation of CK1\u03b1 in del(5q) MDS","volume":"523","author":"Kr\u00f6nke","year":"2015","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.bneo.2025.100119_bib14","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/ng.3984","article-title":"Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells","volume":"49","author":"Meyers","year":"2017","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.bneo.2025.100119_bib15","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.cell.2017.01.013","article-title":"Gene essentiality profiling reveals gene networks and synthetic lethal interactions with oncogenic Ras","volume":"168","author":"Wang","year":"2017","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.bneo.2025.100119_bib16","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.celrep.2016.09.079","article-title":"A CRISPR dropout screen identifies genetic vulnerabilities and therapeutic targets in acute myeloid leukemia","volume":"17","author":"Tzelepis","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.bneo.2025.100119_bib17","article-title":"Extracting biological insights from the project achilles genome-scale CRISPR screens in cancer cell lines","author":"Dempster","year":"2019","journal-title":"bioRxiv"},{"issue":"7753","key":"10.1016\/j.bneo.2025.100119_bib18","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/s41586-019-1103-9","article-title":"Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens","volume":"568","author":"Behan","year":"2019","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.bneo.2025.100119_bib19","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrendo.2015.117","article-title":"Physiological and pathophysiological roles of NAMPT and NAD metabolism","volume":"11","author":"Garten","year":"2015","journal-title":"Nat Rev Endocrinol"},{"issue":"24","key":"10.1016\/j.bneo.2025.100119_bib20","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1182\/blood-2017-10-810028","article-title":"Gene dosage effect of CUX1 in a murine model disrupts HSC homeostasis and controls the severity and mortality of MDS","volume":"131","author":"An","year":"2018","journal-title":"Blood"},{"issue":"7757","key":"10.1016\/j.bneo.2025.100119_bib21","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","article-title":"Next-generation characterization of the Cancer Cell Line Encyclopedia","volume":"569","author":"Ghandi","year":"2019","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.bneo.2025.100119_bib22","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1158\/0008-5472.CAN-21-2428","article-title":"Functional genomic analysis of CDK4 and CDK6 gene dependency across human cancer cell lines","volume":"82","author":"Zhang","year":"2022","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.bneo.2025.100119_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103805","article-title":"Illuminating the druggable genome: pathways to progress","volume":"29","author":"Sharma","year":"2024","journal-title":"Drug Discov Today"},{"issue":"5","key":"10.1016\/j.bneo.2025.100119_bib24","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"issue":"Database issue","key":"10.1016\/j.bneo.2025.100119_bib25","first-page":"D955","article-title":"Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells","volume":"41","author":"Yang","year":"2013","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"10.1016\/j.bneo.2025.100119_bib26","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1158\/1535-7163.MCT-16-0197","article-title":"Dual and specific inhibition of NAMPT and PAK4 By KPT-9274 decreases kidney cancer growth","volume":"15","author":"Abu Aboud","year":"2016","journal-title":"Mol Cancer Ther"},{"issue":"21","key":"10.1016\/j.bneo.2025.100119_bib27","first-page":"7436","article-title":"FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis","volume":"63","author":"Hasmann","year":"2003","journal-title":"Cancer Res"},{"issue":"17","key":"10.1016\/j.bneo.2025.100119_bib28","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1182\/blood-2012-03-416776","article-title":"Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1\/2) inhibition","volume":"120","author":"Cea","year":"2012","journal-title":"Blood"},{"issue":"51","key":"10.1016\/j.bneo.2025.100119_bib29","doi-asserted-by":"crossref","first-page":"35182","DOI":"10.1074\/jbc.M114.580159","article-title":"Depletion of the central metabolite NAD leads to oncosis-mediated cell death","volume":"289","author":"Del Nagro","year":"2014","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.bneo.2025.100119_bib30","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s10495-009-0334-x","article-title":"Necrostatin-1 reverts shikonin-induced necroptosis to apoptosis","volume":"14","author":"Han","year":"2009","journal-title":"Apoptosis"},{"issue":"15","key":"10.1016\/j.bneo.2025.100119_bib31","doi-asserted-by":"crossref","first-page":"19367","DOI":"10.18632\/oncotarget.8346","article-title":"Necrostatin-1 enhances the resolution of inflammation by specifically inducing neutrophil apoptosis","volume":"7","author":"Jie","year":"2016","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.bneo.2025.100119_bib32","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s00018-022-04526-5","article-title":"Potent anticancer activity of a novel iridium metallodrug via oncosis","volume":"79","author":"Ortega-Forte","year":"2022","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"10.1016\/j.bneo.2025.100119_bib33","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1182\/bloodadvances.2018024182","article-title":"Selective targeting of NAMPT by KPT-9274 in acute myeloid leukemia","volume":"3","author":"Mitchell","year":"2019","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.bneo.2025.100119_bib34","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.stem.2020.07.021","article-title":"Nicotinamide metabolism mediates resistance to venetoclax in relapsed acute myeloid leukemia stem cells","volume":"27","author":"Jones","year":"2020","journal-title":"Cell Stem Cell"},{"issue":"10","key":"10.1016\/j.bneo.2025.100119_bib35","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.stem.2021.06.004","article-title":"Nicotinamide phosphoribosyltransferase inhibitors selectively induce apoptosis of AML stem cells by disrupting lipid homeostasis","volume":"28","author":"Subedi","year":"2021","journal-title":"Cell Stem Cell"},{"issue":"6","key":"10.1016\/j.bneo.2025.100119_bib36","doi-asserted-by":"crossref","first-page":"947","DOI":"10.2217\/17460751.2.6.947","article-title":"Toxicity testing using hematopoietic stem cell assays","volume":"2","author":"Clarke","year":"2007","journal-title":"Regen Med"},{"issue":"3","key":"10.1016\/j.bneo.2025.100119_bib37","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0887-2333(03)00012-2","article-title":"Myeloid clonogenic assays for comparison of the in vitro toxicity of alkylating agents","volume":"17","author":"Volpe","year":"2003","journal-title":"Toxicol In Vitro"},{"issue":"427","key":"10.1016\/j.bneo.2025.100119_bib38","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan8735","article-title":"PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL+ human leukemia","volume":"10","author":"Lai","year":"2018","journal-title":"Sci Transl Med"},{"issue":"10","key":"10.1016\/j.bneo.2025.100119_bib39","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrm.2017.53","article-title":"The multifaceted roles of PARP1 in DNA repair and chromatin remodelling","volume":"18","author":"Ray Chaudhuri","year":"2017","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"9","key":"10.1016\/j.bneo.2025.100119_bib40","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41389-020-00264-0","article-title":"Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) with OT-82 induces DNA damage, cell death, and suppression of tumor growth in preclinical models of Ewing sarcoma","volume":"9","author":"Gibson","year":"2020","journal-title":"Oncogenesis"},{"issue":"9","key":"10.1016\/j.bneo.2025.100119_bib41","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood.2020009195","article-title":"Loss of a 7q gene, CUX1, disrupts epigenetically driven DNA repair and drives therapy-related myeloid neoplasms","volume":"138","author":"Imgruet","year":"2021","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.bneo.2025.100119_bib42","doi-asserted-by":"crossref","first-page":"4798","DOI":"10.1038\/s41388-020-1332-2","article-title":"EZH2 has a non-catalytic and PRC2-independent role in stabilizing DDB2 to promote nucleotide excision repair","volume":"39","author":"Koyen","year":"2020","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.bneo.2025.100119_bib43","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1158\/0008-5472.CAN-21-0688","article-title":"Recruitment of KMT2C\/MLL3 to DNA damage sites mediates DNA damage responses and regulates PARP inhibitor sensitivity in cancer","volume":"81","author":"Chang","year":"2021","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.bneo.2025.100119_bib44","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.stem.2016.08.007","article-title":"DNA damage-induced HSPC malfunction depends on ROS accumulation downstream of IFN-1 signaling and bid mobilization","volume":"19","author":"Tasdogan","year":"2016","journal-title":"Cell Stem Cell"},{"issue":"14","key":"10.1016\/j.bneo.2025.100119_bib45","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1158\/0008-5472.CAN-16-3079","article-title":"Nicotinic acid phosphoribosyltransferase regulates cancer cell metabolism, susceptibility to NAMPT inhibitors, and DNA repair","volume":"77","author":"Piacente","year":"2017","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.bneo.2025.100119_bib46","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.bbrc.2017.07.143","article-title":"Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD+ biosynthesis pathway and NAMPT mutation","volume":"491","author":"Guo","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"10.1016\/j.bneo.2025.100119_bib47","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","article-title":"SynergyFinder plus: toward better interpretation and annotation of drug combination screening datasets","volume":"20","author":"Zheng","year":"2022","journal-title":"Genomics Proteomics Bioinformatics"},{"issue":"23","key":"10.1016\/j.bneo.2025.100119_bib48","doi-asserted-by":"crossref","first-page":"5806","DOI":"10.1158\/0008-5472.CAN-21-1784","article-title":"Are CRISPR screens providing the next generation of therapeutic targets?","volume":"81","author":"Vazquez","year":"2021","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.bneo.2025.100119_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110400","article-title":"Systematic illumination of druggable genes in cancer genomes","volume":"38","author":"Jiang","year":"2022","journal-title":"Cell Rep"},{"issue":"7","key":"10.1016\/j.bneo.2025.100119_bib50","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1182\/bloodadvances.2023010435","article-title":"Monosomy 7\/del(7q) cause sensitivity to inhibitors of nicotinamide phosphoribosyltransferase in acute myeloid leukemia","volume":"8","author":"Eldfors","year":"2024","journal-title":"Blood Adv"},{"issue":"20","key":"10.1016\/j.bneo.2025.100119_bib51","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1182\/blood-2018-10-881441","article-title":"A stemness screen reveals C3orf54\/INKA1 as a promoter of human leukemia stem cell latency","volume":"133","author":"Kaufmann","year":"2019","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bneo.2025.100119_bib52","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2012-04-426965","article-title":"CUX1 is a haploinsufficient tumor suppressor gene on chromosome 7 frequently inactivated in acute myeloid leukemia","volume":"121","author":"McNerney","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2025.100119_bib53","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/1097-0320(20010501)44:1<65::AID-CYTO1083>3.0.CO;2-Q","article-title":"Oncosis is associated with exposure of phosphatidylserine residues on the outside layer of the plasma membrane: a reconsideration of the specificity of the annexin V\/propidium iodide assay","volume":"44","author":"Lecoeur","year":"2001","journal-title":"Cytometry"},{"key":"10.1016\/j.bneo.2025.100119_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.970553","article-title":"Review of various NAMPT inhibitors for the treatment of cancer","volume":"13","author":"Wei","year":"2022","journal-title":"Front Pharmacol"},{"issue":"7","key":"10.1016\/j.bneo.2025.100119_bib55","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1001\/jamadermatol.2016.0401","article-title":"Efficacy and safety of APO866 in patients with refractory or relapsed cutaneous T-cell lymphoma: a phase 2 clinical trial","volume":"152","author":"Goldinger","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"7","key":"10.1016\/j.bneo.2025.100119_bib56","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1038\/s41375-019-0692-5","article-title":"OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis","volume":"34","author":"Korotchkina","year":"2020","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.bneo.2025.100119_bib57","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1158\/1078-0432.CCR-20-3724","article-title":"Targeting DNA damage repair functions of two histone deacetylases, HDAC8 and SIRT6, sensitizes acute myeloid leukemia to NAMPT inhibition","volume":"27","author":"Zhang","year":"2021","journal-title":"Clin Cancer Res"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025000548?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025000548?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:00:45Z","timestamp":1762657245000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328025000548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2950328025000548"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100119","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NAMPT haploinsufficiency is a collateral lethal therapeutic vulnerability in high-risk myeloid malignancies with TP53 inactivation","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100119","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100119"}}